AUGUSTA
UNIVERSITY

Jun. 7, 2019

Xiaoyan Cao
Review Editor at JoVE
JOVE
MS: “CRISPR/CAS9 TECHNOLOGY IN RESTORING DYSTROPHIN EXPRESSION IN IPSC-DERIVED MUSLCE PROGENITORS”

Dear Editor(s):

On behalf of the co-authors and myself, I am writing to request that you consider our manuscript, “CRISPR/CAS9 TECHNOLOGY IN RESTORING DYSTROPHIN EXPRESSION IN IPSC-DERIVED MUSLCE PROGENITORS," for publication in JOVE. We have revised twice based on reviewers' critiques.

Duchenne muscular dystrophy (DMD) is a progressive disease caused by an X-linked recessive mutation of the dystrophin gene. In this manuscript, we introduce a feasible protocol of using CRISPR/Cas9 deletion strategy to restore dystrophin expression in iPSC-derived MPC, which has significant potential for developing future therapies for the treatment of DMD.

The work presented in this manuscript has not been reported previously, nor is it being considered for publication by any other journal. All authors have read, reviewed and approved the data presented in this manuscript.

Thank you for your generous consideration of our work.

Sincerely,

Yaoliang Tang

Yaoliang Tang, MD, PhD, FAHA,
Professor of Medicine
Vascular Biology Center
Medical College of Georgia at Augusta University,
1459 Laney Walker Blvd, Augusta, GA 30912, USA.
Email: yaotang@augusta.edu